The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Organic Cation Transporters Are Determinants of Oxaliplatin Cytotoxicity
Open accessAbstract
Although the platinum-based anticancer drugs cisplatin, carboplatin, and oxaliplatin have similar DNA-binding properties, only oxaliplatin is active against colorectal tumors. The mechanisms for this tumor specificity of platinum-based compounds are poorly understood but could be related to differences in uptake. This study shows that the human organic cation transporters (OCT) 1 and 2 (SLC22A1 and SLC22A2) markedly increase oxaliplatin, but not cisplatin or carboplatin, accumulation and cytotoxicity in transfected cells, indicating that oxaliplatin is an excellent substrate of these transporters. The cytotoxicity of oxaliplatin was greater than that of cisplatin in six colon cancer cell lines [mean ± SE of IC50 in the six cell lines, 3.9 ± 1.4 μmol/L (oxaliplatin) versus 11 ± 2.0 μmol/L (cisplatin)] but was reduced by an OCT inhibitor, cimetidine, to a level similar to, or even lower than that of, cisplatin (29 ± 11 μmol/L for oxaliplatin versus 19 ± 4.3 μmol/L for cisplatin). Structure-activity studies indicated that organic functionalities on nonleaving groups coordinated to platinum are critical for selective uptake by OCTs. These results indicate that OCT1 and OCT2 are major determinants of the anticancer activity of oxaliplatin and may contribute to its antitumor specificity. They also strongly suggest that expression of OCTs in tumors should be investigated as markers for selecting specific platinum-based therapies in individual patients. The development of new anticancer drugs, specifically targeted to OCTs, represents a novel strategy for targeted drug therapy. The results of the present structure-activity studies indicate specific tactics for realizing this goal. (Cancer Res 2006; 66(17): 8847-57)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cellular processing of platinum anticancer drugs
Wang, D., & Lippard, S. J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1691 · Cited by 3,801
Self-citationAlley, M. C., Scudiero, D. A., Monks, A. P., Hursey, M. L., Czerwiński, M., Fine, D. L., Abbott, B. J., Mayo, J. G., Shoemaker, R. H., & Boyd, M. R. (1988) · PubMed · Cited by 3,082
Current Status of Platinum-Based Antitumor Drugs
Wong, E., & Giandomenico, C. M. (1999) · Chemical Reviews · doi:10.1021/cr980420v · Cited by 1,800
Takahara, P. M., Rosenzweig, A. C., Frederick, C. A., & Lippard, S. J. (1995) · Nature · doi:10.1038/377649a0 · Cited by 769
Self-citationLebwohl, D., & Canetta, R. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00224-x · Cited by 754
Oxaliplatin: A review of preclinical and clinical studies
Raymond, E., Chaney, S. G., Taamma, A., & Cvitkovic, E. (1998) · Annals of Oncology · doi:10.1023/a:1008213732429 · Cited by 643
Cloning and Characterization of Two Human Polyspecific Organic Cation Transporters
GORBOULEV, V., ULZHEIMER, J. C., AKHOUNDOVA, A., ULZHEIMER-TEUBER, I., KARBACH, U., QUESTER, S., BAUMANN, C., LANG, F., BUSCH, A. E., & KOEPSELL, H. (1997) · DNA and Cell Biology · doi:10.1089/dna.1997.16.871 · Cited by 638
Rixe, O., Ortuzar, W., Alvarez, M., Parker, R., Reed, E., Paull, K., & Fojo, T. (1996) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)81490-6 · Cited by 615
The role of DNA mismatch repair in platinum drug resistance.
Fink, D. A., Nebel, S., Aebi, S. P., Zheng, H., Cenni, B., Nehmé, A., Christen, R. D., & Howell, S. B. (1996) · PubMed · Cited by 597
Cisplatin and DNA repair in cancer chemotherapy
Zamble, D. B., & Lippard, S. J. (1995) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)89095-7 · Cited by 538
Self-citation
Cited by
Koepsell, H., Lips, K., & Volk, C. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9254-z · Cited by 988
Effect of Genetic Variation in the Organic Cation Transporter 1, OCT1, on Metformin Pharmacokinetics
Shu, Y., Brown, C., Castro, R., Shi, R., Lin, E., Owen, R., Sheardown, S., Yue, L., Burchard, E., Brett, C., et al. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100275 · Cited by 477
Self-citationCiarimboli, G., Deuster, D., Knief, A., Sperling, M., Holtkamp, M., Edemir, B., Pavenstädt, H., Lanvers-Kaminsky, C., am Zehnhoff-Dinnesen, A., Schinkel, A. H., et al. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090610 · Cited by 444
Nanocarriers for delivery of platinum anticancer drugs
Oberoi, H. S., Nukolova, N. V., Kabanov, A. V., & Bronich, T. K. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.014 · Cited by 396
Nies, A. T., Koepsell, H., Damme, K., & Schwab, M. (2011) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-14541-4_3 · Cited by 375
Metadata
- Authors
- Zhang, S., Lovejoy, K. S., Shima, J. E., Lagpacan, L. L., Shu, Y., Lapuk, A., Chen, Y., Komori, T., Gray, J. W., Chen, X., Lippard, S. J., & Giacomini, K. M.
- Venue
- Cancer Research
- Published
- 2006-09-01
- Volume
- 66
- Issue
- 17
- Pages
- 8847-8857
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2122023026
- Cited by
- 431
- References
- 44
- FWCI
- 10.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Organic Cation Transporters Are Determinants of Oxaliplatin Cytotoxicity. https://app.cochat.ai/papers/10.1158/0008-5472.can-06-0769
- The paper
- Zhang, S., Lovejoy, K. S., Shima, J. E., Lagpacan, L. L., Shu, Y., Lapuk, A., Chen, Y., Komori, T., Gray, J. W., Chen, X., Lippard, S. J., & Giacomini, K. M. (2006). Organic Cation Transporters Are Determinants of Oxaliplatin Cytotoxicity. Cancer Research. https://doi.org/10.1158/0008-5472.can-06-0769
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
